Showing results (281-290 of 301) with videos related to

Sort By:
Pageof 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CarcinomaMichael H Brave, William F Maguire, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2022
FDA Approval Summary: Cabozantinib for Differentiated Thyroid CancerElizabeth S Duke, Amy K Barone, Somak Chatterjee, et al.
The Oncologist|July 6, 2024
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutationsGautam U Mehta, Paz J Vellanki, Yi Ren, et al.
Drugs|November 5, 2018
Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic ModalitiesMathew Suji Eapen, Philip M Hansbro, Anna-Karin Larsson-Callerfelt, et al.
Chemosphere|January 10, 2020
Association between chronic arsenic exposure and the characteristic features of asthmaAbu Eabrahim Siddique, Mizanur Rahman, Md Imam Hossain, et al.
Science Translational Medicine|July 5, 2013
Natural selection in a bangladeshi population from the cholera-endemic ganges river deltaElinor K Karlsson, Jason B Harris, Shervin Tabrizi, et al.
Elife|October 16, 2019
Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammationAtiqur Rahman, Katherine M Henry, Kimberly D Herman, et al.
Toxicology and Applied Pharmacology|April 12, 2021
T helper 2-driven immune dysfunction in chronic arsenic-exposed individuals and its link to the features of allergic asthmaAtiqur Rahman, Md Shofikul Islam, Selim Reza Tony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situBrian L Heiss, Elaine Chang, Hee-Koung Joeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Pageof 31